- Zacks•3 hours ago
Allergan plc (AGN) announced that the FDA has approved the Natrelle Inspira Cohesive line of breast implants for breast reconstruction, augmentation or revision surgery.
- TheStreet.com•4 days ago
Gilead Sciences' (GILD) NASH liver disease pipeline is "very attractive," Gabelli said in an analyst note on Thursday.
- Barrons.com•4 days ago
Credit Suisse Teva Pharmaceutical Industries and Allergan both took eye-opening steps in announcing deals to bring in new pipeline assets that may help drive mid- to longer-term growth. Of the two, Teva’s (TEVA) new partnership with Regeneron Pharmaceuticals (REGN) on fasinumab seems a little more reasonable to us when considering the price paid and the clearer overlap with Teva’s existing infrastructure, while Allergan’s (AGN) decision to pay a very large premium (especially when the contingent value rights (CVRs) are factored in) to move into the non-alcoholic steatohepatitis (NASH) space through the acquisition of Tobira Therapeutics (TBRA) was more of a surprise to us. Teva has highlighted pain as one of their core areas of focus so a collaboration to obtain access to Regeneron’s fasinumab ties in to strategy.
NYSE - NYSE Delayed Price. Currency in USD
As of 4:03 PM EDT. Market open.
|Day's Range||0.00 - 0.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||N/A|
|Dividend & Yield||N/A (N/A)|